The European market for PV devices is a dynamic market that will grow through 2029, driven by the availability of new products backed by clinical data. However, market revenues will be hindered to some extent by declining ASPs resulting from pricing pressures, increasing competition, and the impact of COVID-19 pandemic.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for PV devices in Europe across a 10-year period.

The COVID-19 pandemic will have a minimal impact on overall PV procedures and revenues in 2020.

What factors will contribute to the negative impact on the PV device market?

What is the recovery outlook for procedure volumes, sales, and revenues over the forecast period?

A meta-analysis was published in 2018 that showed an increased risk of death associated with paclitaxel-coated balloons and stents after 2 years.

How has this study impacted the European markets for DCBs and DES?

How has this study impacted physicians' perception of these products?

Which companies will be affected and how?

What strategies are the concerned companies employing to counteract the effects of the study?

Competitors are developing DES and DCBs that do not use paclitaxel.

What companies are developing these products?

What impact will the approval of such products have on use of existing devices?

DCBs and DES manufacturers have invested in clinical trials to expand their offerings in indications such as BTK.

Which trials will impact the adoption of DCBs and DES for the BTK indication?

What has been physicians' preferred approach to treat lesions in the BTK indication?

Budgetary constraints continue to affect the European PV device market.

What effects are GPOs having on the European PV device market?

How fast will ASPs erode and which countries will experience the greatest erosion?

How can companies mitigate this downward pricing pressure?

Table of contents

  • Peripheral Vascular Devices - Market Insights - Europe Part 2

Author(s): Bishwjit Ghoshal, MBA

Bishwjit Ghoshal is an analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in interventional oncology and vascular access device markets. Bishwjit holds a Bachelor's degree in Pharmacy from the University of Delhi and an MBA in Pharmaceutical Marketing from the National Institute of Pharmaceutical Education and Research, Mohali.

Follow Bishwjit on twitter: @Bishwjit_DRG